SIGA Technologies

SIGA "designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGA’s leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including smallpox. Additional programs target arenaviruses such as Lassa fever, filoviruses such as Ebola and Marburg, flaviviruses such as Dengue fever, and other category A diseases."

Board
Accessed May 2010:


 * Eric A. Rose, M.D., Chief Executive Officer and Chairman of the Board
 * Ayelet Dugary, Chief Financial Officer
 * Dennis E. Hruby, Ph.D., Chief Scientific Officer
 * James J. Antal
 * Michael J. Bayer
 * Thomas E. Constance
 * Steven L. Fasman
 * Scott M. Hammer
 * Joseph W. "Chip" Marshall, III
 * Paul G. Savas
 * Bruce Slovin
 * Michael Weiner

Contact
URL: http://www.siga.com